Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00. Following the sale, the director now owns 2,071,931 shares in the company, valued at approximately $221,945,248.72. The sale was disclosed in a filing with the SEC, which is available through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Stock Performance

Shares of MRNA traded down $1.87 on Friday, reaching $105.14. 2,415,948 shares of the company's stock traded hands, compared to its average volume of 4,300,259. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The stock's 50 day simple moving average is $99.71 and its two-hundred day simple moving average is $93.52. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24. The stock has a market cap of $40.26 billion, a PE ratio of -8.47 and a beta of 1.62.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same period last year, the business posted $3.61 earnings per share. The business's revenue for the quarter was down 44.9% on a year-over-year basis. On average, analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRNA. HSBC reiterated a "reduce" rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada reiterated an "outperform" rating and issued a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. Canaccord Genuity Group raised their target price on Moderna from $82.00 to $91.00 and gave the company a "hold" rating in a report on Friday, February 23rd. Needham & Company LLC restated a "hold" rating on shares of Moderna in a report on Thursday. Finally, Jefferies Financial Group restated a "buy" rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $126.49.

Institutional Trading of Moderna

A number of large investors have recently bought and sold shares of MRNA. Douglas Lane & Associates LLC boosted its holdings in shares of Moderna by 36.4% in the third quarter. Douglas Lane & Associates LLC now owns 355,177 shares of the company's stock worth $36,686,000 after acquiring an additional 94,810 shares during the period. International Assets Investment Management LLC boosted its stake in Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company's stock valued at $38,552,000 after buying an additional 381,808 shares during the period. ARK Investment Management LLC boosted its stake in Moderna by 81.7% during the third quarter. ARK Investment Management LLC now owns 259,838 shares of the company's stock valued at $26,839,000 after buying an additional 116,840 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Moderna during the third quarter valued at $1,185,000. Finally, Invesco Ltd. boosted its stake in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after buying an additional 517,683 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.